metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
	pembrolizumab alone
	KEYNOTE-048 (P vs C ; all population), 2019 Lancet 2019; 394:1915-1928 Adv Ther 2021 Apr 15. J Clin Oncol 2022; 40:2321-2332-. NCT02358031	RCT	mHNSCC - L1 - all population	pembrolizumab	cetuximab with chemotherapy (platine plus 5FU)	patients with recurrent or metastatic squamous cell carcinoma of the head and neck, untreated locally incurable recurrent or metastatic HNSCC	301 / 300	some concern	inconclusive	suggested 17 % decrease in deaths (OS) (PE) statistically significant 34 % increase in progression or deaths (PFS) (PE) statistically significant 64 % decrease in objective responses (ORR)
	pembrolizumab plus 5FU plus platin
	KEYNOTE-048 (PC vs C ; all population), 2019 Lancet 2019; 394:1915-1928 Adv Ther 2021 Apr 15. NCT02358031	RCT	mHNSCC - L1 - all population	pembrolizumab plus 5 FU plus platine	cetuximab plus 5 FU plus platine	patients with recurrent or metastatic squamous cell carcinoma of the head and neck, untreated locally incurable recurrent or metastatic HNSCC	281 / 278	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) inconclusive 8 % decrease in progression or deaths (PFS) (PE) suggested 28 % decrease in deaths (OS) (extension)